Disc Medicine finalised the pivotal Phase III trial design of bitopertin in erythropoietic protoporphyria (EPP) with the FDA ...

Disc Medicine is in strong financial shape, advancing key candidates. Find out why IRON stock could be a strong investment ...

Disc Medicine has finalized the design of the confirmatory trial for its rare blood disorder drug candidate, adding a ...

Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under ...

Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May ...

Chlorcyclizine shows promise in reducing protoporphyrin-IX accumulation and liver damage in erythropoietic protoporphyria, ...

Disc Medicine, Inc. (NASDAQ:IRON), a biotechnology company focused on developing treatments for rare blood disorders, has ...

House Republicans revealed their proposed rules package for the 119th Congress and it includes a measure to restrict Title IX protections for trans people. The proposed rules package – which the ...

At the heart of Biden’s Title IX rules is an attempt to redefine sex in federal law, a move that has faced significant legal challenges. One such case, State of Kansas v. U.S. Department of ...

Department of Materials and Optoelectronic Science, Center for Functional Polymers and Supramolecular Materials, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan ...